- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04608461
Effect of Pumpkin Seeds in the Treatment of Moderate to Severe Palmar Arsenical Keratosis
October 28, 2020 updated by: Rokshana Khatun, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Arsenicosis is a major health problem in Bangladesh.
Long term exposure of arsenic causes keratosis of palm which reduce working capacity of patient.
It also causes massive skin lesions like Bowen's disease which has a risk to develop squamous cell carcinoma.
Pumpkin seed is well known for its antioxidant and anticancer properties.
So this study will be conducted to identify the compound from pumpkin seeds and to see its outcome on keratosis.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Contamination of groundwater by arsenic is a global problem affecting thousands of people worldwide, especially in Bangladesh, India and West Bengal.
In Bangladesh, an estimated 59 administrative districts out of 64 have been affected with significantly high concentrations of arsenic.
Due to arsenicosis, keratosis of palm and sole reduce the patient's working capacity and affect the socioeconomic condition.
Bowen's disease, squamous cell carcinoma and basal cell carcinoma which are invasive skin lesions also caused by arsenicosis.
Keratosis can be treated by various topical preparations like salicylic acid, alpha-lipoic acid, zinc, propylene glycol, garlic oil, neem leaf extract, an extract of Azadirachta indica and Solanum melongena.
But these treatments require a longer time to relieve symptoms and thus reduce patient's compliance.
Pumpkin seeds are rich not only in antioxidant vitamins (carotenoids and tocopherols), minerals and proteins, but also low in fat and calories.
β-carotene reduces the damage of skin from the sun and it also acts as an anti-inflammatory agent.
α-carotene slows the aging process, prevents tumor growth and reduces the risk of developing cataracts.
Vitamin E also called tocopherols protects the cell from oxidative damage by preventing oxidation of cell membranous unsaturated fatty acid.
β-sitosterol also useful to reduce blood cholesterol and to decrease the risks of some types of cancers.
So this study will be conducted to see the outcome of pumpkin seed extract in moderate to severe palmar arsenical keratosis.
The study will be an open phase-II clinical trial and will be conducted in Bangabandhu Sheikh Mujib Medical University and Sirajdikhan Upazila of Munshiganj District.
Extract from pumpkin seeds will be collected by using 70% ethanol as a solvent and rotary evaporator.
Thin Layer Chromatography (TLC) of extract will be done to identify the compound.
By using brine shrimp bioassay cytotoxicity assay will be done.
The ointment will be prepared from pumpkin seeds extract and supplied to each patient at an interval of 2 weeks.
Each patient will be advised about applying the cream.
Improvement and adverse effects will be monitored through phone calls and during the visit regularly.
Clinical improvement will be assessed by measuring the palmar arsenical nodule size before and after completion of treatment and perception of patients about their improvement.
Statistical analysis and results will be documented in different diagrams and in tabulated forms.
Study Type
Interventional
Enrollment (Anticipated)
23
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Munshiganj, Bangladesh, 1540
- Recruiting
- Sirajdikhan
-
Contact:
- Rokshana Khatun, MBBS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Presence of moderate to severe palmar arsenical keratosis
- Drinking arsenic contaminated water for at least six months
- Patient voluntarily agreed to participate
Exclusion Criteria:
- Age less than 19 years or more than 65 years
- Pregnant and nursing mother
- Skin diseases like atopic dermatitis eczema and psoriasis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: pumpkin seeds extract containing cream
Intervention-pumpkin seeds extract containing cream, dose-twice daily for 12 weeks
|
Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Keratotic nodular size
Time Frame: 12 weeks
|
Nodular size and lesion size will be measured by slide calipers
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 17, 2019
Primary Completion (ANTICIPATED)
December 5, 2020
Study Completion (ANTICIPATED)
December 5, 2020
Study Registration Dates
First Submitted
October 3, 2020
First Submitted That Met QC Criteria
October 28, 2020
First Posted (ACTUAL)
October 29, 2020
Study Record Updates
Last Update Posted (ACTUAL)
October 29, 2020
Last Update Submitted That Met QC Criteria
October 28, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BSMMU/2019/9986
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keratotic Nodular Size
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...UnknownKeratotic Nodular SizeBangladesh
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingKeratotic Nodular SizeBangladesh
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...UnknownKeratotic Nodular SizeBangladesh
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...UnknownKeratotic Nodular SizeBangladesh
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...UnknownImprovement of Keratotic Nodular SizeBangladesh
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...UnknownKeratotic Nodular SizeBangladesh
-
Hamisu SalihuCompletedFetal Body Size | Fetal Brain SizeUnited States
-
Centre Hospitalier Intercommunal CreteilRecruiting
-
University of LiverpoolMedical Research CouncilCompletedPortion SizeUnited Kingdom
-
University of LiverpoolMedical Research CouncilCompleted
Clinical Trials on Pumpkin seed extract containing cream
-
Greenyn Biotechnology Co., Ltd.Taipei Medical UniversityRecruitingDiabetes | Metabolic DiseaseTaiwan
-
Northwestern UniversityRecruitingOveractive Bladder (OAB)United States
-
Greenyn Biotechnology Co., Ltd.Taipei Medical University WanFang HospitalCompleted
-
Texas Woman's UniversityCompletedHypertension | DyslipidemiaUnited States
-
Marymount UniversityCompletedHypertension | Elevated Blood PressureUnited States
-
Texas Woman's UniversityCompleted
-
OmniSolutions Laboratory Holdings LimitedCompletedUrinary Incontinence | Urinary FrequencyChina
-
Medicus Research, LLCCompletedBlood Pressure
-
Chulalongkorn UniversityUnknown
-
Universidade Federal do Rio de JaneiroRio de Janeiro State Research Supporting Foundation (FAPERJ)Completed